Medicines Patent Pool

Plus: Medicines Patent Pool sets goal for growth and Boehringer’s Spevigo meets psoriasis endpoint and updates from Junshi, Simcere and Ribon  

Plus: AbbVie gains LPAR1 antibody via $255M buy of DJS and updates for Denali, the U.K., Kite-Refuge, Takeda-Zedira, Immunic, Talaris, Celeris

NIH has quadrupled the pool’s technologies and secured it trifecta of countermeasure types: vaccines, antivirals and diagnostics

The pharma says it’s been committed to broad access from the start and continues to respond to global needs

Plus Argenx’s efgartigimod meets and updates from Oric, Aligos, ITM and more

Plus China stocks rise again, Deepcell raises and updates from Qbic, AbbVie and more

WHO backing mRNA vaccine capacity, Korea providing a global biomanufacturing training center

After a slow start, WHO’s C-TAP is gaining momentum

Plus COVID deal expands global access to molnupiravir and updates from 

Plus InflaRx, Vumerity, Twist, Synthace, Molecular Partners, Merck KGaA, Sotio-LegoChem and Kezar